Compare GSIW & HBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GSIW | HBIO |
|---|---|---|
| Founded | 2016 | 1901 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Laboratory Analytical Instruments |
| Sector | | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.6M | 33.8M |
| IPO Year | 2023 | 2000 |
| Metric | GSIW | HBIO |
|---|---|---|
| Price | $0.13 | $0.73 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $2.50 |
| AVG Volume (30 Days) | 299.7K | ★ 682.2K |
| Earning Date | 01-01-0001 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $5,368,221.00 | ★ $87,371,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $7.22 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 283.23 | N/A |
| 52 Week Low | $0.09 | $0.28 |
| 52 Week High | $1.79 | $2.28 |
| Indicator | GSIW | HBIO |
|---|---|---|
| Relative Strength Index (RSI) | 39.19 | 53.17 |
| Support Level | $0.13 | $0.71 |
| Resistance Level | $0.14 | $0.80 |
| Average True Range (ATR) | 0.01 | 0.06 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 12.65 | 28.35 |
Garden Stage Ltd is a Hong Kong-based financial services provider principally engaged in the provision of placing and underwriting services; securities dealing and brokerage services; and asset management services. Its business is carried out through its wholly owned Operating Subsidiaries: I Win Securities, which is licensed to conduct Type 1 (dealing in securities) regulated activities under the SFO in Hong Kong; and I Win Asset Management, which is licensed to conduct Type 4 (advising on securities) and Type 9 (asset management) regulated activities under the SFO in Hong Kong.
Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, specialized products and services that enable fundamental research, pharmaceutical and therapy discovery, bioproduction, and pre-clinical testing for drug development. Its primary focus is scientific instruments used to advance life sciences and research. With operations in North America, Europe and china it sells through a combination of direct and distribution channels to customers around the world. The product brands of the company include Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, and Panlab. The majority of its revenue comes from the United States.